Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare

Summary

Eli Lilly is setting aside up to $3.25 billion to acquire InnoCare Pharma, continuing its acquisition spree that includes deals with Kelonia Therapeutics and Centessa Pharmaceuticals valued at up to $7 billion and $7.8 billion, respectively.